Amp Volatility Score
Catalyst Info & Data Links
TITLE: ATI-450 for Rheumatoid Arthritis Phase 2a Clinical Trial
WHAT IS THE NEXT CATALYST EVENT?
Phase 2a Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Wang C, Hockerman S, Jacobsen EJ, Alippe Y, Selness SR, Hope HR, Hirsch JL, Mnich SJ, Saabye MJ, Hood WF, Bonar SL, Abu-Amer Y, Haimovich A, Hoffman HM, Monahan JB, Mbalaviele G. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018 May 7;215(5):1315-1325. doi: 10.1084/jem.20172063. Epub 2018 Mar 16. PMID: 29549113; PMCID: PMC5940269.
MECHANISM OF ACTION
ATI-450 is an investigational oral small molecule inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) inflammatory signaling pathway. This pathway drives the expression of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals. Key inflammatory cytokines driven by this pathway include tumor necrosis factor α (TNFα), interleukin-1α and -1β (IL1α and IL1β), and interleukin-6 (IL6). On the basis of this mechanism, Aclaris is developing ATI-450 as a potential treatment for immuno-inflammatory diseases.
Updated by MV
#ATI450 #Rheumatoidarthritis #ACRS #autoimmunedisease #inflammatorydisease
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post